Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9316462 | 0.73 | TIPARP (0.35) | NAMPTTIPARPIRAK4AOC3 | |
| SCHEMBL30298085 | 0.72 | NAMPT (0.37) | NAMPTTIPARPGRM1KMT2AKDM4E | |
| SCHEMBL31157566 | 0.67 | NAMPT (0.35) | NAMPTTIPARPKMT2AKDM4E | |
| SCHEMBL30298037 | 0.65 | CSF1R (0.39) | NAMPTGRM1KMT2A | |
| SCHEMBL31157527 | 0.64 | NAMPT (0.36) | NAMPTTIPARPGRM1KMT2AKDM4E | |
| SCHEMBL9651894 | 0.64 | HDAC6 (0.35) | TIPARPAOC3CYP2C9 | |
| SCHEMBL31157489 | 0.62 | CSF1R (0.38) | TIPARPKDM4ECYP2C9 | |
| Hydrochloric Acid SCHEMBL31157585 | 0.61 | TIPARP (0.41) | TIPARPGRM1IRAK4KMT2AKDM4E | |
| SCHEMBL31157433 | 0.61 | LMNA (0.38) | NAMPTIRAK4KMT2AKDM4E | |
| SCHEMBL31157592 | 0.60 | LMNA (0.37) | TIPARPKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376100-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | Redona Therapeutics, Inc. | 2024-11-14 | — | — | US | disclosed |
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376100-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | PAPSS1, OTUD7B, BRD7 | NAMPT 2241/4885TIPARP 1522/4885MAT2A 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.